Paromomycin

Mechanism-of-action class: Protein Synthesis Inhibitors.

• Paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (NOTE-It is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of HUMATIN™ Capsules and other antibacterial drugs, HUMATIN™ Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

• Paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. It is also contraindicated in intestinal obstruction.contraindicated

Intestinal amebiasis: Adults and Pediatric Patients: Usual dose—25 to 35 mg/kg body weight daily, administered in three doses with meals, for five to ten days. Management of hepatic coma: Adults: Usual dose—4 g daily in divided doses, given at regular intervals for five to six days.

Nausea, abdominal cramps, and diarrhea have been reported in patients on doses over 3 g daily. To report SUSPECTED ADVERSE REACTIONS, Waylis Therapeutics LLC at 844-200-7910 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

• Dec 14, 2007ANDAANDA065173Heritage

1. 1Diarrhoea2121%
2. 2Abdominal Pain Upper109.8%
3. 3Vomiting87.8%
4. 4Nausea76.9%
5. 5Tinnitus76.9%
6. 6Abdominal Pain65.9%
7. 7Anaemia65.9%
8. 8Asthenia65.9%
9. 9Dysphagia65.9%
10. 10Pain65.9%
11. 11Rash65.9%
12. 12Urinary Tract Infection65.9%
13. 13Blood Creatinine Increased54.9%
14. 14Dyspepsia54.9%
15. 15Fluid Retention54.9%

Recent PubMed references pinned to Paromomycin as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Antileishmanial and Immunomodulatory Activity of Paclitaxel and Docetaxel Combined with Miltefosine and Paromomycin.
  International journal of molecular sciences · 2026 · Melcón-Fernández E, Balaña-Fouce R, García-Estrada C, et al.
  PMID 41977242DOI 10.3390/ijms27073055
• The adverse effects of paromomycin on early cardiovascular development in zebrafish (Danio rerio).
  Aquatic toxicology (Amsterdam, Netherlands) · 2026 · Lin Y, Lei Y, Zhong Y, et al.
  PMID 41905306DOI 10.1016/j.aquatox.2026.107795
• Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasis.
  International journal of antimicrobial agents · 2026 · Chu WY, Singh OP, Sundar S, et al.
  PMID 41519406DOI 10.1016/j.ijantimicag.2026.107713
• The Efficacy of Topical Paromomycin-Gentamicin versus Topical Paromomycin Alone in The Treatment of Cutaneous Leishmaniasis: A meta-analysis of randomized controlled trials.
  Sultan Qaboos University medical journal · 2025 · Alshaikh T, Jihad M, Jomaa A, et al.
  PMID 41425839DOI 10.18295/2075-0528.2931
• Efficacy of topical hydrophilic gel of paromomycin combined with systemic or locally administered leishmanicidal drugs for treatment of experimental leishmaniasis caused by Leishmania (Viannia) braziliensis.
  The Journal of antimicrobial chemotherapy · 2025 · Alves LL, Pinheiro Rosa DC, Freire ML, et al.
  PMID 41054941DOI 10.1093/jac/dkaf362
• Synergistic Effect of Copper Nanoparticles and Paromomycin in the Treatment of Cutaneous Leishmaniasis.
  Parasite immunology · 2025 · Heidari-Kharaji M, Rodrigues P, Ferreira C, et al.
  PMID 40686227DOI 10.1111/pim.70017
• Paromomycin is a more effective selection agent than kanamycin in Arabidopsis harboring the neomycin phosphotransferase II transgene.
  PloS one · 2025 · Goodman CP, Padgett VN, Evans ER, et al.
  PMID 40561069DOI 10.1371/journal.pone.0325322
• Solid Lipid Nanoparticles Encapsulated With Paromomycin: An Effective Oral Formulation Against Leishmania major in Mouse Model.
  Parasite immunology · 2025 · Heidari-Kharaji M, Rodrigues P, Petersen C, et al.
  PMID 39988879DOI 10.1111/pim.70002

The 10 most recently updated of 37 ClinicalTrials.gov registrations naming Paromomycin as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)
  Not yet recruiting · Phase 3 · Interventional · 900 enrolled · Institute of Tropical Medicine, Belgium
  NCT07463040updated 2026-03-10
• LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study
  Completed · Phase 2 · Interventional · 52 enrolled · Drugs for Neglected Diseases
  NCT05957978updated 2025-12-18
• A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis
  Active not recruiting · Observational · 216 enrolled · University of York
  NCT04342715updated 2025-07-24
• Paromomycin or Metronidazole for Symptomatic Dientamoeba Fragilis in Adults
  Recruiting · Interventional · 60 enrolled · Sheba Medical Center
  NCT06907498updated 2025-04-02
• Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa
  Completed · Phase 3 · Interventional · 439 enrolled · Drugs for Neglected Diseases
  NCT03129646updated 2024-02-29
• Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)
  Unknown · Phase 2 · Interventional · 250 enrolled · Dr. Frank Arguello Cancer Clinic
  NCT02366884updated 2022-04-06
• A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3
  Completed · Phase 2 · Interventional · 68 enrolled · National Institute of Allergy and Infectious Diseases (NIAID)
  NCT00000771updated 2021-11-04
• Patients Response to Early Switch To Oral:Osteomyelitis Study
  Terminated · Early phase 1 · Interventional · 11 enrolled · Julio Ramirez
  NCT02099240updated 2021-04-06
• A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis
  Completed · Phase 2 · Interventional · 48 enrolled · U.S. Army Medical Research and Development Command
  NCT01536795updated 2021-02-12
• Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia
  Completed · Phase 2 · Phase 3 · Interventional · 80 enrolled · Fundacion Nacional de Dermatologia
  NCT03096457updated 2021-02-02

CPIC-curated drug–gene pairs for Paromomycin. Levels describe the strength of curated evidence and guideline status — never a recommendation to test or to adjust therapy.

• MT-RNR1CPIC A
  MT-RNR1 and Aminoglycosides

Frequently asked questions

How does Paromomycin work?

Mechanism-of-action class: Protein Synthesis Inhibitors.

What is Paromomycin used for?

According to FDA labeling, Paromomycin carries indications including: Paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (NOTE-It is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of HUMATIN™ Capsules and other antibacterial drugs, HUMATIN™ Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What class of drug is Paromomycin?

Paromomycin is classified as Antibiotics, Antiprotozoal, Protein Synthesis Inhibitors, Decreased Protein Synthesis.

What are the brand names for Paromomycin?

Paromomycin is marketed under brand names including Humatin.

What are the contraindications for Paromomycin?

Paromomycin labeling lists contraindications including: Paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. It is also contraindicated in intestinal obstruction.. Always consult the full prescribing information and a clinician.